Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 19/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10363175 | 0.89 | FLT1 (0.42) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL15086682 | 0.87 | FLT1 (0.42) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL982075 | 0.85 | FLT1 (0.42) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL4079695 | 0.79 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL10364834 | 0.78 | PDE5A (0.39) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL5764666 | 0.78 | MAPK14 (0.42) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL4079593 | 0.78 | MAPK14 (0.40) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL30538004 | 0.77 | FLT1 (0.57) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL4130612 | 0.77 | FLT1 (0.43) | FLT1MAPK11MINK1MAPK14 | |
| SCHEMBL4132478 | 0.77 | MAPK14 (0.43) | FLT1MAPK11MINK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222273-B2 | Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases | PFIZER LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | PFIZER LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | CYP1B1, UBE2V1, CYP4B1 | FLT1 1543/4885MAPK11 2887/4885MINK1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.